会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Epoxy resin composition
    • 环氧树脂组合物
    • US07141627B2
    • 2006-11-28
    • US10693693
    • 2003-10-27
    • Satoshi IdemuraMasao YamadaKoichi FujimotoKatsuji Takahashi
    • Satoshi IdemuraMasao YamadaKoichi FujimotoKatsuji Takahashi
    • C08G63/181C08G63/19C08G63/193C08L63/00C08L63/04
    • C08G59/22C08L63/00H05K1/0326C08L2666/18
    • An epoxy resin cured article has a high glass transition temperature and low dissipation factor. An epoxy resin composition from which the cured article can be having excellent solubility in solvents is used to produce the cured articles. A polyester as a curing agent of an epoxy resin composition having an aromatic polyhydroxy coumpound residue including an aryloxycarbonyl group at the molecule of the terminal, an aromatic polyvalent hydrocarbon group residue, and bulky structure, is used. Since the curing agent behaves as a polyfunctional curing agent, a cured article produced therefrom has a high crosslink density. Since highly polar hydroxyl groups are not formed during curing, a cured article has high glass transition temperature and a low dissipation factor. The cured article does not release low molecular weight carboxylic acids though hydrolysis of ester bonds at crosslinked bonds. Since the polyester has a bulky structure, the crystallization of the molecular chain is prevented and the solubility of the epoxy resin composition containing the polyester is excellent.
    • 环氧树脂固化制品玻璃化转变温度高,散热系数低。 使用固化物可以在溶剂中具有优异溶解性的环氧树脂组合物来制造固化物。 作为环氧树脂组合物的固化剂的聚酯,其具有在末端分子中含有芳氧基羰基的芳香族多羟基固体残基,芳香族多价烃基残基和大体积结构。 由于固化剂表现为多官能固化剂,因此由其制备的固化物具有高交联密度。 由于固化时不会形成高极性的羟基,所以固化物的玻璃化转变温度高,散热系数低。 固化物通过在交联键上的酯键水解而不释放低分子量羧酸。 由于聚酯具有庞大的结构,因此防止了分子链的结晶,并且含有聚酯的环氧树脂组合物的溶解性优异。
    • 15. 发明授权
    • Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their
therapeutic use
    • 血管紧张素II拮抗剂1-联苯甲基咪唑化合物及其治疗用途
    • US5616599A
    • 1997-04-01
    • US378650
    • 1995-01-26
    • Hiroaki YanagisawaKoichi FujimotoYoshiya AmemiyaYasuo ShimojiTakuro KanazakiHiroyuki KoikeToshio Sada
    • Hiroaki YanagisawaKoichi FujimotoYoshiya AmemiyaYasuo ShimojiTakuro KanazakiHiroyuki KoikeToshio Sada
    • C07D233/90C07D403/10C07D405/12C07D405/14C07F7/18C07D257/04A61K31/41A61K31/415
    • C07D403/10C07D233/90C07D405/12C07D405/14C07F7/1856
    • Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
    • 下式(I)或式(I)的化合物p:其中R 1是烷基或链烯基; R2和R3是与环烷基稠合的氢,烷基,烯基,环烷基,芳烷基,芳基或芳基; R4是氢,烷基,烷酰基,烯酰基,芳基羰基,烷氧基羰基,四氢吡喃基,四氢噻喃基,四氢噻吩基,四氢呋喃基,式-SiRaRbRc的基团,其中R a,R b和R c是烷基或芳基,烷氧基甲基,(烷氧基烷氧基)甲基,卤代烷氧基甲基, 芳烷基,芳基或烷酰氧基甲氧基羰基; R5是羧基或-CONR8R9,其中R8和R9的氢或烷基,或R8和R9一起形成亚烷基; R6是氢,烷基,烷氧基或卤素; R7是羧基或四唑-5-基; Rp1为氢,烷基,环烷基或烷酰基; Rp2是单键,亚烷基或亚烷基; Rp3和Rp4各自为氢或烷基; Rp6是羧基或四唑-5-基; Xp为氧或硫; 及其药学上可接受的盐和酯。 化合物是AII受体拮抗剂,因此具有低血压活性,可用于治疗和预防高血压。 该化合物可以通过使联苯甲基化合物与咪唑化合物反应来制备。
    • 19. 发明授权
    • Benzamidine derivatives
    • 苄脒衍生物
    • US06555556B1
    • 2003-04-29
    • US10132042
    • 2002-04-25
    • Koichi FujimotoFumitoshi AsaiHayao Matsuhashi
    • Koichi FujimotoFumitoshi AsaiHayao Matsuhashi
    • A61K31445
    • C07D211/46
    • Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: wherein R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R2 represents a hydrogen atom, a halogen atom or an alkyl group, R3 represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R4 and R5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R6 represents a substituted pyrrolidine group or substituted piperidine group.
    • 式(I)的苄脒衍生物或其药学上可接受的盐对因子Xa具有优异的抑制活性,可用于治疗或预防凝血障碍:其中R1表示氢原子,卤素原子,烷基或羟基; R2表示氢原子,卤素原子或烷基,R3表示氢原子,可以具有取代基的烷基,芳烷基,可以具有取代基的烷酰基或任意取代的烷基磺酰基,R4和R5与 各自表示氢原子,卤素原子,任选取代的烷基,烷氧基,羧基,烷氧基羰基或任选取代的氨基甲酰基,R 6表示取代的吡咯烷基或取代的哌啶基 。